ProCE Banner Activity

IMpower133: Addition of Atezolizumab to First-line Carboplatin/Etoposide in Extensive-Stage Small-Cell Lung Cancer

Slideset Download
Conference Coverage
In this study, patients receiving atezolizumab plus carboplatin/etoposide showed significantly prolonged OS and PFS vs carboplatin/etoposide alone.

Released: September 28, 2018

Expiration: September 27, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology